Tokyo, Japan

Tomohiro Morio

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Lymphotec Inc.. Active years: 2013.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tomohiro Morio: Innovator in Hematopoietic Stem Cell Survival

Introduction

Tomohiro Morio is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of hematopoietic stem cell research. His innovative work focuses on enhancing the survival of transplanted hematopoietic stem cells, which is crucial for successful medical treatments.

Latest Patents

Morio holds a patent for a method that promotes the survival of transplanted hematopoietic stem cells. The patent describes a composition that utilizes HLA matched activated lymphocytes, which are proliferated and activated from mononuclear cells separated from peripheral blood or umbilical cord blood. This composition is designed to prevent survival failure of transplanted hematopoietic stem cells and to promote their survival. The administration of this composition can vary based on patient conditions, with a recommended dose of a humanized antibody ranging from 0.2 to 20 ml/kg/day.

Career Highlights

Morio is associated with Lymphotec Inc., where he continues to advance his research and development efforts. His work is pivotal in the field of regenerative medicine, particularly in improving outcomes for patients undergoing stem cell transplants.

Collaborations

Morio collaborates with esteemed colleagues, including Kenzo Bamba and Yasuyuki Kuroiwa. Their combined expertise contributes to the innovative research and development at Lymphotec Inc.

Conclusion

Tomohiro Morio's contributions to the field of hematopoietic stem cell survival are invaluable. His innovative methods and collaborations are paving the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…